Free Trial
OTCMKTS:KNBWY

Kirin 5/14/2026 Earnings Report

Kirin logo
$16.37 +0.52 (+3.26%)
As of 10:24 AM Eastern

Kirin EPS Results

Actual EPS
$0.21
Consensus EPS
$0.26
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Kirin Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.63 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kirin Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Kirin Earnings Headlines

Kirin (KNBWY) Expected to Announce Earnings on Tuesday
Microscopic Footage Shows Immune Cells Attacking Cancer
Early human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using its TriKE platform, which is designed to keep Natural Killer cells active and targeted longer than standard approaches. The company's next-generation version shows potential for 10-40x greater potency and has already cleared an important FDA milestone. Watch the microscopic footage and see what the next catalyst could mean for investors.tc pixel
KNBWY Kirin Holdings Company, Limited - Seeking Alpha
See More Kirin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kirin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kirin and other key companies, straight to your email.

About Kirin

Kirin (OTCMKTS:KNBWY) Holdings Company, Limited is a Japan-based global beverage and life sciences group best known for its flagship beer brand. The company’s core operations encompass the brewing and distribution of beer and spirits, the production of soft drinks and other non-alcoholic beverages, and a growing pharmaceuticals and biotech segment. Kirin’s beverage portfolio ranges from mainstream lagers and craft-inspired brews to juices, teas, and carbonated soft drinks sold under various regional labels.

Rooted in the founding of Kirin Brewery Company in 1888, the group restructured into a pure holding company in 2007 to foster greater strategic flexibility. Over more than a century of expansion, Kirin has grown beyond Japan to establish a presence across Asia, Oceania, the Americas and Europe. Notable milestones include its majority stake in Australia’s Lion Nathan, partnerships with Chinese soft-drink bottlers, and the 2019 consolidation of its global pharmaceutical operations under Kyowa Kirin Co., Ltd., focusing on oncology, immunology and nephrology therapies.

The company is led by President and CEO Yoshinori Isozaki, who took the helm in April 2021. Under his stewardship, Kirin has emphasized sustainable practices—from water stewardship at its breweries to circular packaging initiatives—and continues to explore growth opportunities in health science through R&D investments. With a diversified business model spanning beverages and life sciences, Kirin Holdings leverages its century-long heritage to pursue innovation and resilience in global markets.

View Kirin Profile